Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3

2005839 citationsJournal Articlebronze Open Access

Authors

Alessandra Mangia · Istituti di Ricovero e Cura a Carattere Scientifico

Rosanna Santoro · Casa Sollievo della Sofferenza

Nicola Minerva · Noosa Hospital

Giovanni Ricci · Sapienza University of Rome

Vito Carretta

Marcello Persico · Federico II University Hospital

F. Vinelli · Ospedali Riuniti di Foggia

Abstract

A shorter course of therapy over 12 weeks with peginterferon alfa-2b and ribavirin is as effective as a 24-week course for patients with HCV genotype 2 or 3 who have a response to treatment at 4 weeks.

Topics & Keywords

Hepatitis C virus research Liver Disease Diagnosis and Treatment Hepatitis B Virus Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 352, Issue 25, pp. 2609-2617

DOI: 10.1056/nejmoa042608

Field-Weighted Citation Impact: 43.15